Date | Dividends Paid | Capital Expenditure | Other Financing Activities | Net Cash Used Provided By Financing Activities |
---|
CEO | Ms. Yan Zhao |
IPO Date | Nov. 12, 2019 |
Location | China |
Headquarters | Tech Development Zone |
Employees | 4,655 |
Sector | Consumer Discretionary |
Industries |
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is headquartered in Jinan, the People's Republic of China.
Past 5 years
USD 1.70
USD 10.27
USD 5.65
USD 23.44
USD 24.83
StockViz Staff
February 3, 2025
Any question? Send us an email